JP6377907B2 - クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 - Google Patents

クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 Download PDF

Info

Publication number
JP6377907B2
JP6377907B2 JP2013532271A JP2013532271A JP6377907B2 JP 6377907 B2 JP6377907 B2 JP 6377907B2 JP 2013532271 A JP2013532271 A JP 2013532271A JP 2013532271 A JP2013532271 A JP 2013532271A JP 6377907 B2 JP6377907 B2 JP 6377907B2
Authority
JP
Japan
Prior art keywords
toxin
amino acid
difficile
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013532271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502253A5 (cg-RX-API-DMAC7.html
JP2014502253A (ja
Inventor
ショーン，クリフォード
ロバーツ，エイプリル
アハーン，ヘレン
メイナード−スミス，マイケル
ランドン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health
Micropharm Ltd
Original Assignee
UK Secretary of State for Health
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Health, Micropharm Ltd filed Critical UK Secretary of State for Health
Publication of JP2014502253A publication Critical patent/JP2014502253A/ja
Publication of JP2014502253A5 publication Critical patent/JP2014502253A5/ja
Application granted granted Critical
Publication of JP6377907B2 publication Critical patent/JP6377907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013532271A 2010-10-05 2011-10-05 クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 Active JP6377907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1016742.7A GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens
GB1016742.7 2010-10-05
PCT/GB2011/051910 WO2012046061A2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens

Publications (3)

Publication Number Publication Date
JP2014502253A JP2014502253A (ja) 2014-01-30
JP2014502253A5 JP2014502253A5 (cg-RX-API-DMAC7.html) 2014-11-13
JP6377907B2 true JP6377907B2 (ja) 2018-08-22

Family

ID=43243528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532271A Active JP6377907B2 (ja) 2010-10-05 2011-10-05 クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原

Country Status (10)

Country Link
US (4) US10369206B2 (cg-RX-API-DMAC7.html)
EP (1) EP2625193B1 (cg-RX-API-DMAC7.html)
JP (1) JP6377907B2 (cg-RX-API-DMAC7.html)
CN (1) CN103237807B (cg-RX-API-DMAC7.html)
AU (1) AU2011311321B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013008407A2 (cg-RX-API-DMAC7.html)
CA (1) CA2812731C (cg-RX-API-DMAC7.html)
GB (1) GB201016742D0 (cg-RX-API-DMAC7.html)
SG (1) SG189058A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012046061A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
DK2714910T3 (en) * 2011-05-27 2018-02-05 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112014013876A2 (pt) * 2011-12-08 2019-09-24 Novartis Ag vacina à base de toxina de clostridium difficile
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013352034B2 (en) * 2012-11-28 2018-08-02 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
EP2988778A4 (en) * 2013-04-22 2016-12-14 Board Of Regents Of The Univ Of Oklahoma CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
GB201309421D0 (en) * 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
CN103772509B (zh) * 2014-01-20 2017-01-11 山东国际生物科技园发展有限公司 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
US12252515B2 (en) * 2018-01-16 2025-03-18 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
US11136360B2 (en) * 2018-12-19 2021-10-05 Tsinghua University Fusion proteins comprising a Mtu ΔI-CM intein variant and methods of protein purification
US11560235B2 (en) * 2021-02-09 2023-01-24 Joby Aero, Inc. Aircraft propulsion unit
CN113717263B (zh) * 2021-08-04 2022-06-07 河北医科大学第二医院 一种艰难梭菌特异性抗原肽
CN115093470B (zh) * 2022-06-30 2023-03-24 广州市乾相生物科技有限公司 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用
CN120484111B (zh) * 2025-05-14 2025-10-28 广州海绿生物技术有限公司 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP2002514886A (ja) * 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
AU2002232078A1 (en) 2001-02-09 2002-08-19 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe Clostridium difficile vaccine
ES2533492T3 (es) * 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
CN101500581B (zh) 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
US20120020996A1 (en) 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
BR112013027229B1 (pt) * 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante

Also Published As

Publication number Publication date
CA2812731A1 (en) 2012-04-12
SG189058A1 (en) 2013-05-31
US12491239B2 (en) 2025-12-09
CN103237807A (zh) 2013-08-07
WO2012046061A2 (en) 2012-04-12
CA2812731C (en) 2021-07-06
US10369206B2 (en) 2019-08-06
EP2625193A2 (en) 2013-08-14
BR112013008407A2 (pt) 2016-06-21
US20210369830A1 (en) 2021-12-02
EP2625193B1 (en) 2018-04-04
GB201016742D0 (en) 2010-11-17
AU2011311321A1 (en) 2013-04-11
JP2014502253A (ja) 2014-01-30
WO2012046061A3 (en) 2012-12-20
AU2011311321B2 (en) 2016-05-19
US20130266583A1 (en) 2013-10-10
US20230165949A1 (en) 2023-06-01
CN103237807B (zh) 2016-10-26
US20190328859A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP6377907B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原
EP2844283B1 (en) Clostridium difficile antigens
Bartolini et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro
US8883172B2 (en) Chemically modified peptides with improved immunogenicity
MX2008015814A (es) Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
CA2652103C (en) Anthrax vaccine
JP2012526059A (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
US10406221B2 (en) Lipidated Streptococcus pneumoniae antigen compositions, methods of preparation and use
US11278609B2 (en) Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
HK1185621B (en) Clostridium difficile antigens
HK1185621A (en) Clostridium difficile antigens
HK1202805B (en) Clostridium difficile antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140925

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161114

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20161222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20161227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170116

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180726

R150 Certificate of patent or registration of utility model

Ref document number: 6377907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250